Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Patients undergoing elective unilateral total hip replacement or a revision of at least 1 component of a total hip replacement.~* Patients who were willing and able to undergo bilateral ascending contrast venography~* Either sex, any race, 18 years and older~Key Exclusion Criteria~* Known or suspected bleeding or coagulation disorder in the patient or his or her first-degree relative~* Known or suspected history of heparin-induced thrombocytopenia~* Known coagulopathy~* Active bleeding or at high risk for bleeding~* Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days~* Active hepatobiliary disease~* Alcohol and/or substance abuse within the past year~* Any condition for which surgery or administration of an anticoagulant is contraindicated~* Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure \>180 mm Hg or supine diastolic blood pressure \>105 mm Hg~* Clinically significant laboratory abnormalities at the enrollment visit:~* Hemoglobin \<10 g/dL~* Platelet count \<100,000/mm\^3~* Creatinine clearance \<30 mL/min, as estimated by the method of Cockcroft and Gault~* Alanine aminotransferase or aspartate aminotransferase \>2\*upper limit of normal or a total bilirubin ≥ 1.5\*1 (unless an alternative causative factor such as Gilbert's syndrome was identified)~* Need for ongoing treatment with a parenteral or oral anticoagulant (eg, subjects with mechanical valves, warfarin eligible atrial fibrillation)~* Current use of dextrans or fibrinolytics~* Treatment with medications affecting coagulation or platelet function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban, 2.5 mg BID plus placebo (Type: ACTIVE_COMPARATOR): Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
- Enoxaparin, 40 mg QD plus placebo (Type: EXPERIMENTAL): Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID

Based on this trial design, predict the completion outcome and termination type (if applicable).